Ligand Pharmaceuticals (NASDAQ:LGND) acquired two privately held companies that strengthen and complement its OmniAb® technology platform.
xCella Biosciences was acquired for $7M in cash plus potential earnouts, and Taurus Biosciences for $5M in cash plus non-transferable contingent value rights.
In addition, Ligand will invest $2.5M in a new company, Minotaur Therapeutics, which will be led by Taurus Biosciences’ founder, in exchange for royalties on products from future programs.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.